ELTXNasdaqPharmaceutical PreparationsUS GAAP · USD

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapy product candidates for cancer, with its lead program ELI-002 7P aimed at mKRAS-driven tumors. The company does not yet have approved products or product revenue and is still centered on research, clinical development, and intellectual property protection.

Kysy yhtiöstä
Liikevoitto (EBIT)−37,7milj. USD
+16,2 %v/v
Nettotulos−39,6milj. USD
+23,8 %v/v
Vapaa kassavirta−37,0milj. USD
+0,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−60−40−2002040milj. USD2020: 2,9 milj. USD2020: EBIT −55 milj. USD20202021: 28 milj. USD2021: EBIT −39 milj. USD20212022: 2,3 milj. USD2022: EBIT −24 milj. USD20222023: EBIT −36 milj. USD20232024: EBIT −45 milj. USD20242025: EBIT −38 milj. USD2025−38
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Elicio Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage oncology immunotherapy0 %

Lead and pipeline therapeutic candidates designed to treat cancer through immune-based mechanisms.

Preclinical drug discovery0 %

Early-stage programs and discovery work intended to generate future clinical candidates.

Platform technology licensing and development0 %

AMP platform and related intellectual property used to support internal development and potential partnering.

Collaboration and licensing arrangements0 %

Potential non-product revenue sources such as partnerships, licenses, or similar strategic deals.

Research and development services0 %

Internal and outsourced R&D activities supporting clinical and preclinical advancement.

Asiakkaat

Elicio does not currently sell approved products, so its near-term counterparties are primarily clinical investigators, contract research organizations, manufacturers, and potential licensing partners rather than end-market patients. If its programs succeed, future customers would include oncology physicians, hospitals, and payors that adopt the approved therapies. The company’s commercial opportunity is therefore still dependent on regulatory success and on whether partners or healthcare systems see clinical and reimbursement value.

Clinical development partners

Investigators, CROs, and CMOs that execute trials, manufacture materials, and support regulatory development.

Strategic licensing partners

Biopharma companies that may license or collaborate on the AMP platform or pipeline assets.

Future oncology providers

Hospitals and oncology physicians that would prescribe the therapy if approved and clinically adopted.

Future payors

Government and private payors that would determine coverage and reimbursement after approval.

Strategia

Elicio’s strategy is to advance ELI-002 7P into late-stage clinical trials, move preclinical programs into the clinic, and broaden its pipeline around its AMP platform. It also aims to protect its intellectual property, pursue regulatory approvals, and potentially supplement internal development through acquisitions or in-licensing. Because it has no approved products, execution is mainly about converting scientific assets into clinical and regulatory milestones while preserving cash runway.

Advance ELI-002 7P through late-stage developmentLyhyt aikaväli

The lead asset is the main value driver and the clearest path to clinical and regulatory validation.

Broaden the pipeline from preclinical to clinicalKeskipitkä aikaväli

A deeper pipeline reduces single-asset dependence and improves long-term partnering optionality.

Protect intellectual property and platform valuePitkä aikaväli

Patent coverage is central to differentiation, partnering leverage, and eventual commercialization.

Maantiede

Elicio is headquartered in Boston, Massachusetts, and operates as a U.S.-based clinical-stage biotech company. It also has an Australian subsidiary established to support research credit qualification for studies conducted in Australia. The company’s disclosed risk profile highlights reliance on foreign and foreign-owned vendors for certain clinical and discovery activities, which creates supply-chain and regulatory exposure.

Riskit

Elicio faces the classic risks of a clinical-stage biotech: it has no approved products, recurring losses, and a need for substantial additional capital, with management disclosing substantial doubt about going concern. Development, regulatory, manufacturing, and reimbursement outcomes are uncertain, and any delay or failure can materially impair value. The company also depends on patent protection and third-party vendors, including foreign suppliers, which adds IP, supply-chain, and regulatory risk.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Financing and going concern risk1Clinical and regulatory failure2Intellectual property protection3Third-party manufacturing and vendor dependence4Reimbursement and commercialization uncertainty5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Financing and going concern riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company has recurring operating losses and will need additional capital to fund development beyond its current runway.

    KohdistuuResearch and developmentGeneral and administrative spendingClinical trial continuity
  2. Clinical and regulatory failureVaikutus: KorkeaTodennäköisyys: Korkea

    Pipeline value depends on successful trial outcomes and FDA/foreign regulatory approvals, which are inherently uncertain.

    Kohdistuu: ELI-002 7P and preclinical oncology programs

  3. Intellectual property protectionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company’s competitive position relies on patents for the AMP platform and specific cancer programs.

    KohdistuuAMP platformMKRASBRAFTP53 programs
  4. Third-party manufacturing and vendor dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Clinical materials and services are outsourced, so vendor noncompliance or disruption can delay development.

    KohdistuuCMOsCROsForeign or foreign-owned suppliers
  5. Reimbursement and commercialization uncertaintyVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Even if approved, payor coverage and pricing pressure may limit adoption and economics.

    Kohdistuu: Future oncology commercialization in the U.S. and abroad

Kysy Clarifolta: Elicio Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Accrued research and development costs

Clinical and outsourced development services are often billed after work is performed, requiring estimates at period-end.

Vaikutus: Can shift operating expenses between quarters and affect comparability

Going concern assessment

Management states that recurring losses and capital needs create substantial doubt about continued operations.

Vaikutus: Important for liquidity analysis and financing assumptions

Equity-based compensation

As a development-stage public company, stock compensation is likely a meaningful non-cash expense.

Vaikutus: Affects reported operating loss and share-based dilution analysis

Collaboration and license accounting

Any future partnering revenue will depend on contract terms and performance obligations.

Vaikutus: Could materially affect revenue recognition timing if deals are signed

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Xilio Therapeutics, Inc.

XLO · Pharmaceutical Preparations

Eledon Pharmaceuticals, Inc.

ELDN · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Immuneering Corp

IMRX · Pharmaceutical Preparations

Lexeo Therapeutics, Inc.

LXEO · Biological Products, (No Diagnostic Substances)

MAIA Biotechnology, Inc.

MAIA · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Elicio Therapeutics, Inc. (Nasdaq) – Pharmaceutical Preparations | Analyysi – Clarifo